Clinical trial results:
An open, single group, multi-centric, post marketing surveillance (PMS) to monitor the reactogenicity and safety of oral live attenuated human rotavirus (HRV) vaccine, Rotarix™ when administered according to the Prescribing Information (PI) to Indian infants

Summary

EudraCT number	2017-000451-14
Trial protocol	Outside EU/EEA
Global end of trial date	23 April 2010

Results information

Result version number	v1 (current)
This version publication date	20 December 2017
First version publication date	20 December 2017

Trial information

Trial identification

Sponsor protocol code	112896

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00938327
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium,
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, +((44)2089 904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, +((44)2089 904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 April 2010
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 February 2010
Global end of trial reached?	Yes
Global end of trial date	23 April 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the reactogenicity of Rotarix in terms of occurrence of at least one Grade "2" or Grade "3" fever, vomiting or diarrhoea within the 8-day (Day 0-Day 7) follow-up period after any Rotarix vaccination

Protection of trial subjects:

The subjects were observed closely for at least 30 minutes following the administration of vaccine, with appropriate medical treatment readily available in case of a rare anaphylactic reaction

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 August 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	India: 332
Worldwide total number of subjects	332
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	332
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment
Recruitment details: -

Pre-assignment
Screening details: -

Pre-assignment period milestones	
Number of subjects started	332
Number of subjects completed	332

Period 1	
Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms	
Arm title	Rotarix Group

Arm description:

Subjects who had received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.

Arm type	Experimental
Investigational medicinal product name	Rotarix™
Investigational medicinal product code	
Other name	GSK Biologicals' oral live attenuated HRV vaccine
Pharmaceutical forms	Powder and solvent for oral suspension
Routes of administration	Oral use

Dosage and administration details:

Two doses of Rotarix administered orally. First dose administered from the age of 6 weeks. Second dose administered at least 4 weeks after Dose 1. Vaccination course completed by 24 weeks of age

Number of subjects in period 1	Rotarix Group
Started	332
Completed	272
Not completed	60
Consent withdrawn by subject	4
2nd dose received outside of the study	7
Adverse event, non-fatal	2
Vaccine not received as out of stock	9
Lost to follow-up	37
Protocol deviation	1

Baseline characteristics

Reporting groups	
Reporting group title	Rotarix Group
Reporting group description:	
Subjects who had received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.	

Reporting group values	Rotarix Group	Total	
Number of subjects	332	332	
Age categorical Units: Subjects			
Age continuous Units: weeks arithmetic mean standard deviation	 10.4 ± 4.27	 -	
Gender categorical Units: Subjects			
Female	155	155	
Male	177	177	

End points

End points reporting groups

Reporting group title	Rotarix Group

Reporting group description:

Subjects who had received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.

Primary: Number of subjects reporting Grade 2 or 3 symptoms (fever, vomiting or diarrhoea)

End point title	Number of subjects reporting Grade 2 or 3 symptoms (fever, vomiting or diarrhoea)[1]

End point description:

Grade 2 fever was defined as axillary temperature above 38.0 degrees Celsius (°C) and below or equal to 39.0°C. Grade 3 fever was defined as axillary temperature above 39.0°C. Grade 2 vomiting was defined as 2 episodes of vomiting per day. Grade 3 vomiting was defined as at least 3 episodes of vomiting per day. Grade 2 diarrhoea was defined as 4-5 looser than normal stools per day. Grade 3 diarrhoea was defined as at least 6 looser than normal stools per day.

End point type	Primary

End point timeframe:

During the 8-day (Day 0 – Day 7) follow-up period after each vaccination.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this primary end point was descriptive, no statistical hypothesis test was performed.

End point values	Rotarix Group			
Subject group type	Reporting group			
Number of subjects analysed	332			
Units: subjects				
subjects	42			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting solicited general symptoms

End point title	Number of subjects reporting solicited general symptoms

End point description:

Cough: Cough/runny nose of any intensity Diarrhoea: Passage of three or more looser than normal stools within a day Irritability: Cried more than usual Loss of appetite: Ate less than usual Temperature: Axillary temperature greater than or equal to 37.5°C Vomiting: One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day

End point type	Secondary

End point timeframe:

During the 8-day (Day 0 – Day 7) follow-up period after each vaccination

End point values	Rotarix Group			
Subject group type	Reporting group			
Number of subjects analysed	332			
Units: subjects				
Cough	43			
Diarrhoea	14			
Irritability	81			
Loss of appetite	46			
Temperature (axillary)	24			
Vomiting	67			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting unsolicited adverse events (AEs)

End point title	Number of subjects reporting unsolicited adverse events (AEs)

End point description:

Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

End point type	Secondary

End point timeframe:

During the 31-day (Day 0 – Day 30) follow-up period after each vaccination

End point values	Rotarix Group			
Subject group type	Reporting group			
Number of subjects analysed	332			
Units: subjects				
subjects	23			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting serious adverse events (SAEs)

End point title	Number of subjects reporting serious adverse events (SAEs)

End point description:

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

End point type	Secondary

End point timeframe:

Throughout the study period (from Day 0 up to Day 30)

End point values	Rotarix Group			
Subject group type	Reporting group			
Number of subjects analysed	332			
Units: subjects				
subjects	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events: throughout the study period (Day 0-Day 30). Other adverse avents: during the 8-day (Day 0-Day 7) follow-up period after each vaccination.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	13.0

Reporting groups

Reporting group title	Rotarix Group

Reporting group description:

Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.

Serious adverse events	Rotarix Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 332 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Rotarix Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	133 / 332 (40.06%)		
Nervous system disorders			
Hypersomnia			
subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
Lethargy			
subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
General disorders and administration site conditions			
Inflammation			

subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	25 / 332 (7.53%)		
occurrences (all)	28		
Eye disorders			
Lacrimation increased			
subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	3 / 332 (0.90%)		
occurrences (all)	3		
Diarrhoea			
subjects affected / exposed	16 / 332 (4.82%)		
occurrences (all)	18		
Flatulence			
subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
Tongue discolouration			
subjects affected / exposed	1 / 332 (0.30%)		
occurrences (all)	1		
Vomiting			
subjects affected / exposed	67 / 332 (20.18%)		
occurrences (all)	83		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	45 / 332 (13.55%)		
occurrences (all)	55		
Rhinorrhoea			
subjects affected / exposed	2 / 332 (0.60%)		
occurrences (all)	2		
Skin and subcutaneous tissue disorders			

Dermatitis atopic subjects affected / exposed occurrences (all)	2 / 332 (0.60%) 2		
Rash vesicular subjects affected / exposed occurrences (all)	1 / 332 (0.30%) 1		
Rash subjects affected / exposed occurrences (all)	1 / 332 (0.30%) 1		
Psychiatric disorders Decreased activity subjects affected / exposed occurrences (all)	1 / 332 (0.30%) 1		
Irritability subjects affected / exposed occurrences (all)	81 / 332 (24.40%) 97		
Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all)	1 / 332 (0.30%) 1		
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	3 / 332 (0.90%) 3		
Otitis media acute subjects affected / exposed occurrences (all)	1 / 332 (0.30%) 1		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	46 / 332 (13.86%) 54		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported